Ferri Lorenzo, Covello Giuseppina, Caciotti Anna, Guerrini Renzo, Denti Michela Alessandra, Morrone Amelia
Neuroscience, Psychology, Pharmacology and Child Health Department, University of Florence, Florence, Italy.
Paediatric Neurology Unit and Laboratories, Neuroscience Department, Meyer Children's Hospital, Florence, Italy.
Mol Ther Nucleic Acids. 2016 Oct 25;5(10):e380. doi: 10.1038/mtna.2016.88.
Fabry disease is a rare X-linked lysosomal storage disorder caused by deficiency of the α-galactosidase A (α-Gal A) enzyme, which is encoded by the GLA gene. GLA transcription in humans produces a major mRNA encoding α-Gal A and a minor mRNA of unknown function, which retains a 57-nucleotide-long cryptic exon between exons 4 and 5, bearing a premature termination codon. NM_000169.2:c.639+861C>T and NM_000169.2:c.639+919G>A GLA deep intronic mutations have been described to cause Fabry disease by inducing overexpression of the alternatively spliced mRNA, along with a dramatic decrease in the major one. Here, we built a wild-type GLA minigene and two minigenes that carry mutations c.639+861C>T and c.639+919G>A. Once transfected into cells, the minigenes recapitulate the molecular patterns observed in patients, at the mRNA, protein, and enzymatic level. We constructed a set of specific double-target U1asRNAs to correct c.639+861C>T and c.639+919G>A GLA mutations. Efficacy of U1asRNAs in inducing the skipping of the cryptic exon was evaluated upon their transient co-transfection with the minigenes in COS-1 cells, by real-time polymerase chain reaction (PCR), western blot analysis, and α-Gal A enzyme assay. We identified a set of U1asRNAs that efficiently restored α-Gal A enzyme activity and the correct splicing pathways in reporter minigenes. We also identified a unique U1asRNA correcting both mutations as efficently as the mutation-specific U1asRNAs. Our study proves that an exon skipping-based approach recovering α-Gal A activity in the c.639+861C>T and c.639+919G>A GLA mutations is active.
法布里病是一种罕见的X连锁溶酶体贮积症,由α-半乳糖苷酶A(α-Gal A)酶缺乏引起,该酶由GLA基因编码。人类GLA转录产生一种编码α-Gal A的主要mRNA和一种功能未知的次要mRNA,后者在第4和第5外显子之间保留一个57个核苷酸长的隐蔽外显子,带有一个提前终止密码子。已报道NM_000169.2:c.639+861C>T和NM_000169.2:c.639+919G>A GLA基因内含子深处的突变通过诱导选择性剪接的mRNA过度表达以及主要mRNA显著减少而导致法布里病。在此,我们构建了一个野生型GLA小基因以及两个携带c.639+861C>T和c.639+919G>A突变的小基因。一旦转染到细胞中,这些小基因在mRNA、蛋白质和酶水平上重现了在患者中观察到的分子模式。我们构建了一组特异性双靶点U1asRNAs来纠正c.639+861C>T和c.639+919G>A GLA突变。通过实时聚合酶链反应(PCR)、蛋白质印迹分析和α-Gal A酶活性测定,在COS-1细胞中将U1asRNAs与小基因瞬时共转染后,评估了U1asRNAs在诱导隐蔽外显子跳跃方面的效果。我们鉴定出一组能有效恢复α-Gal A酶活性并在报告小基因中恢复正确剪接途径的U1asRNAs。我们还鉴定出一种独特的U1asRNA,其纠正这两种突变的效率与针对特定突变的U1asRNAs相同。我们的研究证明,基于外显子跳跃的方法在恢复c.639+861C>T和c.639+919G>A GLA突变中的α-Gal A活性方面是有效的。